Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
|ClinicalTrials.gov Identifier: NCT00449345|
Recruitment Status : Unknown
Verified May 2007 by Assuta Hospital Systems.
Recruitment status was: Recruiting
First Posted : March 20, 2007
Last Update Posted : May 30, 2007
The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable.
In recent years, more specific and sensitive tests based on interferon-gamma secretion to TB antigens have come to market, and most current evidence shows that many mantoux positive persons do not have LTBI. Quantiferon-GOLD is one of these assays.
In this prospective study, we will draw blood for the Quantiferon-GOLD assay in parallel to conventional testing, and perform a cost-effectiveness analysis of the cost of the investigation and treatment of LTBI in health-care workers.
We hypothesize that in spite of the cost of screening healthcare workers with Quantiferon-GOLD tests, the reduction in need for LTBI treatment and associated costs will render the test cost-effective.
|Condition or disease||Intervention/treatment|
|Latent Tuberculosis Infection||Procedure: Blood test for Quantiferon-GOLD assay|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Observational Model:||Defined Population|
|Study Start Date :||May 2007|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00449345
|Contact: David Shitrit, MD||+972 8 946 firstname.lastname@example.org|
|Contact: Ben Fox, MRCP||+972 8 946 email@example.com|
|Community Tuberculosis service||Recruiting|
|Principal Investigator:||David Shitrit, MD||Maccabi Healthcare Services, Israel|